do not combine glp-1 receptor agonists with dpp-4 inhibitors guideline Frontiers do not combine glp-1 receptor
Description
Acta Physiologica Scandinavica

Real-world weight change, adherence, and discontinuation among patients with type 2 diabetes initiating glucagon-like peptide-1 receptor agonists in the UK

This indicates that differences between species may influence outcomes, despite using the same concentration range
GLP-1 agonist to treat obesity and prevent cardiovascular disease: What have we achieved so far

The absence of liver toxicity with orforglipron, despite its primary route of elimination through hepatic CYP3A-mediated metabolism, suggests that the hepatotoxicity observed with danuglipron and lotiglipron was related to the specific chemical structures of those molecules rather than to the class of small-molecule GLP-1 agonists as a whole

Van Gaal, L.F
